PAVmed shares surged over 250% after its subsidiary, Lucid Diagnostics, secured a contract with the US Department of Veterans Affairs to supply its EsoGuard esophageal precancer test. The agreement gives more than nine million veterans access to testing. Trading in PAVM was halted amid heavy buying interest.